# Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia

> **NCT06270030** · PHASE1 · COMPLETED · sponsor: **Corxel Pharmaceuticals** · enrollment: 21 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** LNZ101 (Aceclidine /Brimonidine) ophthalmic solution
- **DRUG:** LNZ100 (Aceclidine) ophthalmic solution
- **DRUG:** Placebo (Vehicle) ophthalmic solution

## Key facts

- **NCT ID:** NCT06270030
- **Lead sponsor:** Corxel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-04
- **Primary completion:** 2024-04-10
- **Final completion:** 2024-04-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06270030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06270030, "Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06270030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*